Department of Pathology, Ohio State University Medical Center, Columbus, OH, USA; Department of Oral Biology, Ohio State University College of Dentistry, Columbus, OH, USA.
Eur J Immunol. 2014 Feb;44(2):450-9. doi: 10.1002/eji.201343477. Epub 2013 Nov 15.
We and others have previously shown that IL-12 is indispensable for immunity and is required for the optimal antiparasitic activity of antimonials in experimental visceral leishmaniasis caused by Leishmania donovani. Here we investigated the role of STAT4 in immunity against L. donovani using STAT4 knockout mice and also determined the effect of STAT4 deficiency in response to antimonial therapy. Upon infection with L. donovani, stat4⁻/⁻ BALB/c and C57BL/6 mice showed enhanced susceptibility to Leishmania during late time points of infection which was associated with a marked reduction in Th1 responses and hepatic immunopathology. Interestingly, these defects in Th1 responses in stat4⁻/⁻ did not impair the antimonial chemotherapy as both stat4⁻/⁻ and WT mice showed comparable levels of parasite clearance from the liver and spleen. These findings highlight the role of STAT4 in immunity to L. donovani infection and also provide evidence that STAT4 is dispensable for antimonial-based chemotherapy.
我们之前的研究表明,IL-12 对于免疫是不可或缺的,对于由利什曼原虫引起的实验性内脏利什曼病中锑剂的最佳抗寄生虫活性也是必需的。在这里,我们使用 STAT4 基因敲除小鼠研究了 STAT4 在对抗利什曼原虫感染中的作用,并确定了 STAT4 缺陷对锑剂治疗的反应。在感染利什曼原虫后,stat4⁻/⁻ BALB/c 和 C57BL/6 小鼠在感染后期对利什曼原虫的易感性增加,这与 Th1 反应的显著减少和肝免疫病理学有关。有趣的是,stat4⁻/⁻中的这些 Th1 反应缺陷并没有损害锑剂化疗,因为 stat4⁻/⁻和 WT 小鼠均显示出从肝脏和脾脏中清除寄生虫的水平相当。这些发现强调了 STAT4 在对抗利什曼原虫感染中的作用,并提供了证据表明 STAT4 对于基于锑剂的化疗是可有可无的。